Metastatic Brain Involvement in Colorectal Cancer: Retrospective Two-Center Study
Overview
This retrospective study analyzed 279 colorectal cancer patients with brain metastases (BM) treated at two German centers. Key findings include a 1.91% BM prevalence in one center, common extracranial metastases, and distinct treatment patterns involving surgery and radiotherapy. Survival analyses identified clinical factors influencing outcomes after BM diagnosis.
Background
Colorectal cancer (CRC) is a leading global malignancy with frequent distant metastases, primarily to liver and lung. Brain metastases occur in 1–4% of CRC patients and are associated with poor prognosis and neurological symptoms. Advances in systemic therapies and neuroimaging have increased BM detection, but optimal treatment strategies remain unclear due to limited evidence. This study aims to characterize clinical features and outcomes of CRC patients with BM to inform management.
Data Highlights
Characteristic
Value
Total patients with CRC and BM
279
Patients in Wuerzburg
135 (48.4%)
Patients in Frankfurt
144 (51.6%)
Prevalence of BM in Wuerzburg
1.91%
Mean age at CRC diagnosis
62.1 years
Mean age at BM diagnosis
65.1 years
Male patients
61.6%
Female patients
38.4%
Synchronous BM
11.1%
Mean interval from CRC to metachronous BM
40.5 months
Primary tumor site: Rectal cancer
48.4%
Liver metastases
50.9%
Lung metastases
64.2%
Bone metastases
22.6%
KRAS mutation (of tested)
54.2%
Surgical resection of BM
36.2%
Radiotherapy received
67.0%
Key Findings
Brain metastases occurred in approximately 1.9% of CRC patients in the Wuerzburg cohort.
Most patients had extracranial metastases: lung (64.2%), liver (50.9%), and bone (22.6%).
KRAS mutations were present in over half (54.2%) of molecularly profiled patients.
Surgical resection of BM was performed in 36.2%, predominantly in patients with single brain lesions.
Radiotherapy was administered to 67% of patients, with differences in modality distribution between centers.
Patients undergoing surgery had fewer liver and bone metastases compared to those without surgery.
Clinical Implications
Clinicians should recognize that brain metastases in CRC, though rare, are associated with widespread systemic disease and poor prognosis. Surgical resection may be considered primarily for patients with limited brain involvement and fewer extracranial metastases. Radiotherapy remains a cornerstone of treatment, with modality choice potentially influenced by institutional practices. Molecular profiling, including KRAS status, may inform systemic therapy decisions but requires further study regarding BM-specific mutations.
Conclusion
This study highlights the clinical characteristics and treatment patterns of CRC patients with brain metastases across two centers, emphasizing the need for individualized multidisciplinary management. Further research is warranted to optimize therapeutic strategies and improve survival outcomes in this challenging patient population.
References
Global Cancer Statistics 2020 -- Colorectal Cancer Incidence and Mortality
Metastatic Patterns in Colorectal Cancer -- Frequency and Prognosis
Brain Metastases in Colorectal Cancer -- Clinical Features and Outcomes
by S. Müller, A. Hendricks, K. Uttinger, M. Kostatin, M. Brüggemann, M. Schrader, B. Polat, S. Flemming, J. F. Lock, C.-T. Germer, A. Wiegering, U. Pession
